Interventional Cardiology
Coronary artery disease
CAD diagnosis, treatment, and outcomes
Emerging pathwayAlso known as: CAD, coronary disease, ischemic heart disease
12,947
Clinical questions
213
Evidence-backed
100
Claims analyzed
Interventional Cardiology
CAD diagnosis, treatment, and outcomes
Synthesized from 213 evidence-backed clinical questions linked to this topic — 48 supporting the intervention, 39 against the intervention, 9 still contested.
Does bio-statin vs placebo improve outcomes in Coronary Artery Disease?
Low Certainty+ Favors benefitbio-statin vs placebo · Cardiac Output
6 studies (22,339,710 patients) provide low-certainty evidence for benefit of bio-statin for Cardiac Output in Coronary Artery Disease.
Does statin vs placebo improve outcomes in Coronary Artery Disease?
Low Certainty+ Favors benefitstatin vs placebo
43 studies (2,684,132 patients) provide low-certainty evidence for benefit of statin for the outcome in Coronary Artery Disease.
Does atypical antidepressants vs placebo improve outcomes in Coronary Artery Disease?
Low Certainty− Favors harmatypical antidepressants vs placebo
8 studies (1,580,972 patients) provide low-certainty evidence against benefit of atypical antidepressants for the outcome in Coronary Artery Disease.
Does aspirin vs placebo improve outcomes in Atherosclerosis?
Low Certainty− Favors harmaspirin vs placebo · Cardiac Output
17 studies (1,515,509 patients) provide low-certainty evidence against benefit of aspirin for Cardiac Output in Atherosclerosis.
Does beta-blockers vs placebo improve outcomes in Coronary Artery Disease?
Low Certainty+ Favors benefitbeta-blockers vs placebo
16 studies (1,279,375 patients) provide low-certainty evidence for benefit of beta-blockers for the outcome in Coronary Artery Disease.
Does psychotropic drug vs placebo improve outcomes in myocardial infarction with coronary artery disease?
Low Certainty+ Favors benefitpsychotropic drug vs placebo
7 studies (917,479 patients) provide low-certainty evidence for benefit of psychotropic drug for the outcome in myocardial infarction with coronary artery disease.
Does everolimus vs placebo improve outcomes in Left Main Coronary Artery Disease?
Insufficient~ Mixed resultseverolimus vs placebo · Left Ventricular Ejection Fraction
27 studies (75,243 patients) provide insufficient evidence with mixed findings regarding everolimus for Left Ventricular Ejection Fraction in Left Main Coronary Artery Disease.
Does statin vs placebo improve outcomes in Diabetes Mellitus, Non-Insulin-Dependent?
Insufficient~ Mixed resultsstatin vs placebo
7 studies (1,134 patients) provide insufficient evidence with mixed findings regarding statin for the outcome in Diabetes Mellitus, Non-Insulin-Dependent.
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does antiplatelet vs placebo improve Myocardial Infarction Hospitalization in Coronary Artery Disease?
Low Certainty+ Favors benefitantiplatelet vs placebo · Myocardial Infarction Hospitalization
Does ticagrelor vs aspirin improve Myocardial Infarction Hospitalization in Coronary Artery Disease?
Low Certainty+ Favors benefitticagrelor vs aspirin · Myocardial Infarction Hospitalization
Inflammatory Hypothesis of CAD
STEMI Management — Wed, Aug 12, 8:00 AM EDT — 7 attended
Demo
Synapse Team — Fri, Jun 19, 3:15 PM EDT — 3 attended
This Week's Session
U Miami Journal Club — Wed, May 20, 3:00 PM EDT
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
Effects of Puerarin on Clinical Parameters, Vascular Endothelial Function, and Inflammatory Factors in Patients with Coronary Artery Disease
Medical Science Monitor — Zhang S — Jan 2019
Complementary role of cardiac computed tomography angiography in the diagnosis of prosthetic aortic valve endocarditis and septic coronary embolism - a case report
Journal of Radiology Case Reports — Boogert T — Feb 2019
Evaluation of a New Carotid Intima-Media Thickness Measurement by B-Mode Ultrasonography Using an Innovative Measurement Software, Intimascope
American Journal of Hypertension — Yanase T — Dec 2006
Inflammation in acute coronary syndromes
Heart — Mulvihill N — Mar 2002
Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Coronary artery disease (also known as CAD, coronary disease, ischemic heart disease). CAD diagnosis, treatment, and outcomes
Synapse tracks 3 specific clinical questions in Coronary artery disease, each synthesized independently from its own trial evidence. They include: "Does antiplatelet vs placebo improve Myocardial Infarction Hospitalization in Coronary Artery Disease?"; "Does ticagrelor vs aspirin improve Myocardial Infarction Hospitalization in Coronary Artery Disease?"; "Does everolimus vs placebo improve outcomes in multivessel coronary artery disease?".
As of 2026-08-15, the scientific consensus on Coronary artery disease is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/coronary-artery-disease.
Deterministic synthesis from Synapse's enriched corpus — 113 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Coronary artery disease paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Coronary artery disease papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
PLoS ONE — González-Juanatey C — Feb 2022